



# Yavapai County

Our Mission: "Yavapai County will serve and protect its citizens through efficient management of all its resources to enhance the lives of those we serve."



**For Immediate Release**

**Monday, November 23, 2020**

**For further information, contact:** Terri Farneti, Public Health Coordinator

928.442.5596

## November 23<sup>rd</sup> Update - Yavapai County Community Health Services Yavapai County reports 396 COVID-19 Cases, 4 Confirmed Deaths over the Weekend

Apache	4,921	Coconino	6,988	Cochise	3,137	Graham	1,933	Greenlee	181
Gila	2,631	La Paz	750	Maricopa	191,503	Mohave	5,643	Navajo	7,654
Pima	36,659	Pinal	15,345	Santa Cruz	3,624	Yavapai	4,641	Yuma	16,826

**2,482,346** Arizonans have been tested for COVID-19, with **302,324** positive results and **6,464** deaths reported statewide. Yavapai County has tested **60,598** residents with **4,641** positive cases (an average of 132 cases per day), **1,816** recovered, and **107** deaths. YRMC West has **22** COVID-19 patients and YRMC East is caring for **11**, with **1** person under investigation (PUI). The Verde Valley Medical Center reports **21** COVID-19 hospitalizations and **no** PUI. The VA reports **5** COVID-19 patients.

New COVID-19 Cases since Friday									
Apache	+180	Coconino	+223	Cochise	+117	Graham	+118	Greenlee	+27
Gila	+117	La Paz	+10	Maricopa	+5,923	Mohave	+160	Navajo	+210
Pima	+1,674	Pinal	+494	Santa Cruz	+156	Yavapai	+396	Yuma	+784

**Good news on the coronavirus vaccine front.** AstraZeneca announced promising results from the late-stage trials of a COVID-19 vaccine. The vaccine does not need to be stored at subzero temperatures like Pfizer's vaccine, and it is a two-dose regimen. AstraZeneca executives said the vaccine is already being manufactured and the first 4 million doses could be ready in December, and 40 million could be delivered in the first quarter of 2021. The United States has pre-ordered 300 million doses of the vaccine.



**The FDA has approved another COVID-19 Antibody Treatment.** The drug, made by the biotech company Regeneron, is the second antibody treatment to win emergency use approval from the FDA. Like Eli Lilly's treatment, this drug is only for the treatment of mild to moderate COVID-19 in people 12 years and older who are at high risk of developing more severe symptoms. It's not for patients who are hospitalized because of COVID-19 or who require oxygen therapy because of the virus. Regeneron said that initial doses will be made available to roughly 300,000 patients through a federal government allocation program. Those patients will not be charged for the drug but may have to pay part of the cost of giving the IV. Both Regeneron's drug and the treatment made by Eli Lilly are synthetic versions of human antibodies that mimic the immune system's ability to fight off harmful pathogens. They bind to the coronavirus and prevent it from invading cells. Both treatments are administered by intravenous infusion.

As with any emergency use authorization, the FDA provides fact sheets about the vaccines and treatments for healthcare providers, patients and caregivers. These fact sheets including dosing instructions, potential side effects and drug interactions.

- ★ **Get your Flu Shot!** Call 771-3321 to make an appointment at YCCHS.
- ★ **Yavapai Emergency Phone Bank for COVID Info:** 928-442-5103 - Monday-Thursday, 8:00– 5:00.
- ★ **County COVID-19 Data, Testing Sites, School & Business Guidelines & Resources:** [www.yavapai.us/chs](http://www.yavapai.us/chs)
- ★ **New ADHS website for Healthy Kids, Open Schools:** <https://azdhs.gov/healthyschools>
- ★ **COVID-19 information en español:** <https://www.azdhs.gov/preparedness/epidemiology-disease-control/infectious-disease-epidemiology/es/covid-19/>